What is the trade name of adagrasib? Comparison of domestic and foreign versions

Adagrasib is a KRAS G12C inhibitor developed by Mirati Therapeutics in the United States. It is used to treat non-small cell lung cancer (NSCLC) and some colorectal cancer (CRC) patients carrying KRAS G12C mutations. The drug was approved by the U.S. FDA in 2022 under the trade name Krazati, becoming the second approved targeted drug targeting the KRAS G12C mutation after Sotorasib. Krazati is administered as an oral tablet, with the recommended dosage being 600 mg twice daily.美国市场上常见包装规格为200mg*180片，足以支持一个月完整疗程。

At present, adagrasib has not been officially approved for marketing in mainland China, nor has it been included in the national medical insurance directory. There is no original drug circulating in the country, so patients who want to use the drug can only purchase it through overseas channels. It is usually recommended to obtain it through legal cross-border pharmacies or international hospitals to ensure drug quality and safety.

随着该药海外认可度的提升，一些国际仿制药生产商也推出了阿达格拉西布的平价替代版本。例如老挝卢修斯制目前已仿制上市该药，并以 LuciAda 作为商品名在当地国家销售。 The specification of this version of the drug is 200mg*90 tablets. The drug ingredients are consistent with Krazati. It is mainly targeted at patients who cannot afford the high-priced original drugs. Although generic drugs strive to be consistent with the original research in terms of bioequivalence, their production processes, regulatory standards and approval mechanisms are different from those in European and American countries. It is still recommended to be under the guidance of a doctor before use.

From the perspective of user experience,The price of LuciAda is significantly lower than that of the original drug Krazati. The price of a box is usually between RMB 2,000 and 3,000, which is more cost-effective than the US version of the original drug, which often costs hundreds of thousands of yuan. However, it should be noted that the current generic version of adagrasib has not been approved for marketing by the China Food and Drug Administration (NMPA). It is still an overseas drug in China and cannot be prescribed directly through regular hospitals.

References：https://www.krazati.com/